Dose Range Finding Study of Bimagrumab in Sarcopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

December 9, 2014

Primary Completion Date

June 26, 2018

Study Completion Date

June 28, 2018

Conditions
Sarcopenia
Interventions
DRUG

bimagrumab

Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

OTHER

placebo

Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.

Trial Locations (58)

1090

Novartis Investigative Site, Brussels

1211

Novartis Investigative Site, Geneva

2100

Novartis Investigative Site, Copenhagen

2400

Novartis Investigative Site, Copenhagen NV

3000

Novartis Investigative Site, Leuven

3021

Novartis Investigative Site, St Albans

4002

Novartis Investigative Site, Basel

5000

Novartis Investigative Site, Adelaide

10117

Novartis Investigative Site, Berlin

11217

Novartis Investigative Site, Taipei

12000

Novartis Investigative Site, Prague

13620

Novartis Investigative Site, Bundang Gu

16499

Novartis Investigative Site, Suwon

27262

Novartis Investigative Site, High Point

28034

Novartis Investigative Site, Madrid

28905

Novartis Investigative Site, Getafe

29303

Novartis Investigative Site, Spartanburg

30501

Novartis Investigative Site, Gainesville

31052

Novartis Investigative Site, Toulouse

32611

Novartis Investigative Site, Gainesville

32804

Novartis Investigative Site, Orlando

33014

Novartis Investigative Site, Miami Lakes

33143

Novartis Investigative Site, Miami

33604

Novartis Investigative Site, Pessac

34295

Novartis Investigative Site, Montpellier

43210

Novartis Investigative Site, Columbus

53706

Novartis Investigative Site, Madison

55905

Novartis Investigative Site, Rochester

62500

Novartis Investigative Site, Brno

72205

Novartis Investigative Site, Little Rock

74601

Novartis Investigative Site, Opava

75013

Novartis Investigative Site, Paris

75150

Novartis Investigative Site, Mesquite

78229

Novartis Investigative Site, San Antonio

90630

Novartis Investigative Site, Cypress

97074

Novartis Investigative Site, Würzburg

101990

Novartis Investigative Site, Moscow

117997

Novartis Investigative Site, Moscow

150003

Novartis Investigative Site, Yaroslavl

190068

Novartis Investigative Site, Saint Petersburg

92093-9405

Novartis Investigative Site, La Jolla

06030-5215

Novartis Investigative Site, Farmington

02115

Novartis Investigative Site, Boston

474-8511

Novartis Investigative Site, Ōbu

440-8510

Novartis Investigative Site, Toyohashi

509 6134

Novartis Investigative Site, Mizunami

630-8581

Novartis Investigative Site, Nara

586-8521

Novartis Investigative Site, Kawachi-Nagano

362-0806

Novartis Investigative Site, Kitaadachigun Inamachi

364-8501

Novartis Investigative Site, Kitamoto

776-8585

Novartis Investigative Site, Yoshinogawa

173 0015

Novartis Investigative Site, Itabashi Ku

204-0021

Novartis Investigative Site, Kiyose

136-0075

Novartis Investigative Site, Koto-ku

208-0011

Novartis Investigative Site, Musashimurayama

02447

Novartis Investigative Site, Seoul

02006

Novartis Investigative Site, Albacete

08024

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY